Advertisement
Advertisement

CLYM

CLYM logo

Climb Bio, Inc. Common Stock

14.00
USD
Sponsored
0.00
0.00%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

13.72

-0.28
-2.00%

Climb Bio, Inc. Common Stock Profile

About

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Info & Links

CEO

Aoife Brennan

Headquarters

20 William Street, Suite 145
Wellesley Hills, MA 02481, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.eliemtx.com

Auditor

PricewaterhouseCoopers LLP

Share holders

13

Employees

28

Climb Bio, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

785.65M

Enterprise Value

741.54M

Enterprise Value/EBITDA(ttm)

-11.18

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

4.52

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-35.60%

Return on Invested Capital(ttm)

-33.10%

Return on Assets(ttm)

-34.41%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-66.35M

Net Income Available to Common(ttm)

-57.62M

Diluted EPS(ttm)

-0.83

Share Statistics

Beta (5Y Monthly)

0.08

52-Week Change

733.33%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

57.44M

Dividend Yield

0.00%

Float4

55.77M

% Held by Insiders

2.60%

% Held by Institutions

69.76%

Balance Sheet

Total Cash(mrq)

183.12M

Total Cash Per Share(mrq)

3.19

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

31.45%

Quick Ratio(mrq)

27.86%

Book Value Per Share(mrq)

4.17

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.33

Free Cash Flow(ytd)

-25.18M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement